FDA's Guide To Mitigating Risks Of Long-Acting Opioids
Executive Summary
Because registries could have an adverse impact on patient access to long-acting and extended-release opioids, FDA is proposing a Risk Evaluation and Mitigation Strategy for the drugs that focuses on educating prescribers and patients about proper prescribing and use of the painkillers. The goal for the REMS is to reduce addiction, unintentional overdose and death resulting from inappropriate prescribing, misuse and abuse of the LA/ER products. If that does not occur with the education programs, FDA leaves the door open for a more vigorous risk management program. Below is a summary of FDA's proposal.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth